Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,7 +4,7 @@
4	4
5	5	= Overview =
6	6
7		-Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. Sierra Oncology is focused on developing an emerging pipeline of next generation therapies that target the DNA Damage Response (DDR) network. Sierra Oncology has a highly experienced management team with a proven track record of success in oncology drug development. Sierra Oncology is an ambitious company, oriented towards achieving the successful registration and commercialization of its product candidates.
	7	+Sierra Oncology (SRRA) is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with cancer. Sierra Oncology is focused on developing an emerging pipeline of next generation therapies that target the DNA Damage Response (DDR) network. Sierra Oncology has a highly experienced management team with a proven track record of success in oncology drug development. Sierra Oncology is an ambitious company, oriented towards achieving the successful registration and commercialization of its product candidates.{{footnote}}https://fintel.io/doc/sec-srra-sierra-oncology-10k-annual-report-2018-february-27-17991{{/footnote}}
8	8
9	9	The company's lead product candidate, SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). Chk1 is a key regulator of cell cycle progression and the DDR replication stress response. In cancer cells, intrinsic replication stress is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in DNA repair machinery (e.g., BRCA1 or FANCA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or RAD50) or other genomic alterations. This replication stress results in persistent DNA damage and genomic instability leading to an increased dependency on Chk1 for survival. Targeted inhibition of Chk1 by SRA737 may therefore be synthetically lethal to cancer cells with elevated intrinsic replication stress and have utility as a monotherapy in a range of tumor indications.
10	10
...	...	@@ -42,7 +42,7 @@
42	42
43	43	Sierra Oncology has funded its operations to date primarily from the issuance and sale of its common stock through public offerings, and its convertible and redeemable convertible preferred stock in private financings and, to a lesser extent, through debt financings and exercises of its preferred stock warrants. As of June 30, 2018, the company had cash and cash equivalents of $125.4 million.
44	44
45		-==== Liquidity and Capital Resources ====
	45	+= Liquidity and Capital Resources =
46	46
47	47	**Capital Resources**
48	48
...	...	@@ -59,3 +59,5 @@
59	59	The company plan to continue to fund its current operating plans’ needs through equity financings or other arrangements. To the extent that the company raise additional capital through future equity financings, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of its existing common stockholders. If the company raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict its operations. There can be no assurance that such additional financing, if available, can be obtained on terms acceptable to it. If Sierra Oncology is unable to obtain such additional financing, the company would need to reevaluate its future operating plans.
60	60
61	61	= References =
	62	+
	63	+{{putFootnotes/}}